comparemela.com

Latest Breaking News On - Genmab - Page 8 : comparemela.com

Genmab Improves Its 2022 Financial Guidance

Genmab Improves Its 2022 Financial Guidance
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Japan
Tokyo
Netherlands
Denmark
Copenhagen
Køavn
New-jersey
United-states
Genmab
Marisol-peron
Genmaba-skalvebod-brygge
Andrew-carlsen

Genmab A/S: Genmab Announces Multiple Abstracts to be Presented at the 64th Annual Meeting and Exposition of the American Society of Hematology (ASH)

Nineteen abstracts accepted, including multiple presentations on the safety and efficacy of investigational epcoritamab (DuoBody-CD3xCD20) in a variety of treatment settings and hematologic malignancies

Netherlands
Cairo
Al-qahirah
Egypt
Louisiana
United-states
Japan
New-orleans
Tokyo
Denmark
Copenhagen
Køavn

Agreement to push Antibody Development forward

International Biotech Genmab has been granted a licencing agreement to progress Scancell’s investigational anti-glycan monoclonal antibody into multiple novel therapeutic products. Click to read more.

Lindy-durrant
International-biotech-genmab
Chief-executive-officer
Antibody
Genmab
Agreement
Anti
Potential
Products
Glycan
Dancer
Lymabregnbspplatform

Genmab A/S: Genmab Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL) and Diffuse Large B-Cell Lymphoma (DLBCL)

Genmab has Submitted Biologics License Application (BLA) to U.S. Food and Drug Administration (FDA) for epcoritamab European Medicines Agency (EMA) has validated Marketing Authorization Application

Copenhagen
Køavn
Denmark
Japan
Tokyo
New-jersey
United-states
Netherlands
Austria
Vienna
Wien
David-freundel

BioNTech SE: BioNTech and Genmab Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates

Collaboration expands to include development of monospecific antibody candidates to address malignant solid tumors Expanded collaboration leverages Genmab's proprietary HexaBody technology platform

Germany
Japan
Tokyo
Netherlands
Denmark
Copenhagen
Køavn
New-jersey
United-states
Sylke-maas
David-freundel
Genmab-duobody

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.